- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06095596
Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
November 21, 2023 updated by: Jiayin Yao, Sixth Affiliated Hospital, Sun Yat-sen University
Efficacy and Safety Analysis of Sequential Treatment of Moderate to Severe Ulcerative Colitis With Vedolizumab and Upadacitinib: A Multicenter Prospective Randomized Controlled Clinical Study
It's of great importance to effectively induce and maintain disease remission in patients with moderate to severe ulcerative colitis (UC).
Vedolizumab (VDZ) is known for its high safety profile and confirmed therapeutic efficacy in UC treatment.
However, according to the experience in clinical practice, the effect onset speed of vedolizumab is relatively slow.
Upadacitinib (UPA), however, works quickly, which complements the defect of slow onset of VDZ induction.
However, the safety of UPA used in situations such as infection and tumors is inferior to that of VDZ, and long-term use requires testing for the risk of adverse events such as deep vein thrombosis.
Therefore, if the advantages of long-term maintenance therapy safety of VDZ and rapid induced remission of UPA are fully utilized, the combination of VDZ and UPA induction for 8 weeks, followed by the use of single drug VDZ in maintenance therapy, can maximize the clinical benefits of UC patients.
Due to the lack of high-level clinical research data at home and abroad, we plan to conduct a multicenter prospective randomized controlled clinical study to provide the evidence-based basis for the efficacy analysis of the sequential treatment of moderate to severe UC patients with VDZ and UPA.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
334
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 501655
- Recruiting
- The Sixth Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Jiayin Yao, Professor
- Phone Number: 13826462890
- Email: yjyin@mail3.sysu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed UC for at least 3 months, including endoscopic evidence supporting UC and histopathological evidence supporting UC diagnosis
- Suffering from moderate to severe UC, defined as modified Mayo score ≥ 4 and endoscopic subscale (ESS) ≥ 2
- Indications for VDZ or UPA application
Exclusion Criteria:
- Patients who are unable to take oral UPA and receive regular intravenous VDZ infusion therapy
- Evidence of toxic megacolon was found during screening
- Previously underwent extensive colectomy, subtotal resection, or total colectomy, ileostomy, or colostomy due to UC
- Subjects who require surgery due to UC or plan to undergo elective surgery during the study period
- There is evidence indicating that the subjects suffer from severe, progressive, or uncontrolled kidney, liver, blood, endocrine, respiratory, mental, or neurological diseases
- Evidence of active hepatitis B or C infection during screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination treatment group
A combination treatment of vedolizumab and upadacitinib for 8 weeks in the induction therapy, then followed by a single treatment of vedolizumab in the maintenance therapy
|
Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.
Other Names:
Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
Other Names:
|
Placebo Comparator: Single treatment group
single treatment of vedolizumab both in the induction and maintenance therapy
|
Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
8th-week endoscopic remission rate
Time Frame: 8th-week
|
endoscopic subscale (ESS) =0, which defined as endoscopic remission
|
8th-week
|
normalization rate of CRP at the 8th week
Time Frame: 8th-week
|
normalization rate of C reactive protein (CRP)
|
8th-week
|
Clinical remission and response rate at the 8th week
Time Frame: 8th-week
|
Clinical remission and response rate
|
8th-week
|
life quality score at the 8th week
Time Frame: 8th-week
|
Inflammatory bowel disease questionnaire (IBDQ), the total score is 32-224, with higher scores indicating better quality of life for patients.
|
8th-week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
normalization rate of CRP at the 54th week
Time Frame: 54th-week
|
normalization rate of CRP
|
54th-week
|
Clinical remission and response rate at the 54th-week
Time Frame: 54th-week
|
Clinical remission and response rate
|
54th-week
|
life quality score at the 54th week
Time Frame: 54th-week
|
Inflammatory bowel disease questionnaire (IBDQ), the total score is 32-224, with higher scores indicating better quality of life for patients.
|
54th-week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2023
Primary Completion (Estimated)
October 31, 2025
Study Completion (Estimated)
October 31, 2026
Study Registration Dates
First Submitted
October 11, 2023
First Submitted That Met QC Criteria
October 18, 2023
First Posted (Actual)
October 23, 2023
Study Record Updates
Last Update Posted (Actual)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 21, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Colonic Diseases
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Crohn Disease
- Colitis
- Colitis, Ulcerative
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Gastrointestinal Agents
- Protein Kinase Inhibitors
- Janus Kinase Inhibitors
- Vedolizumab
- Upadacitinib
Other Study ID Numbers
- 2023ZSLYEC-469
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on Upadacitinib
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
-
AbbVieNot yet recruiting
-
University Hospital, MontpellierRecruitingRheumatoid ArthritisFrance
-
AbbVieActive, not recruitingUlcerative Colitis (UC)United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic... and more
-
AbbVieActive, not recruitingAtopic DermatitisUnited States, Argentina, Australia, Bosnia and Herzegovina, Bulgaria, Canada, China, Colombia, Croatia, Denmark, Estonia, Finland, France, Germany, Italy, Japan, Malaysia, New Zealand, Puerto Rico, Romania, Russian Federation, Sw... and more
-
AbbVieActive, not recruitingAtopic DermatitisUnited States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Netherlands, New Zealand, Portugal, Singapore, Spain, Taiwan, United Kingdom
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
-
AbbVieNot yet recruiting
-
AbbVieActive, not recruitingPsoriatic ArthritisUnited States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
-
AbbVieActive, not recruitingRheumatoid ArthritisUnited States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, ... and more